NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: SUNPHARMA · data 2026-10-31
Sun Pharmaceutical Industries Limited
In plain words
Price: 13.2% below its 52-week high of ₹2,046.9.
Delivery: 57.8% of traded shares were kept for delivery over the last 10 sessions, against 63.5% over the last 60.
Latest results: a net profit of ₹2,903 cr for the quarter ended Dec 2024.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹61,631 cr |
| Net profit (last 12 months) | ₹10,966 cr |
| Sales growth, 3 years (yearly) | 9.9% |
| Profit growth, 3 years (yearly) | 10.6% |
At a glance
Promoters 54.5%, pledged 1.4%, institutions 37.0%.
P/E 38.9, P/B 4.8, dividend yield 0.9%. Price relative to earnings and book value (low is cheaper, not better).
ROE 14.7%, ROCE 17.7%, operating margin 23.2%: how much profit it earns on the money it uses.
Debt/equity 0.06, Profit growth 10.6% and sales growth 9.9% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Virtually debt-free (debt/equity 0.1 or less).
- Healthy operating margin (23.2%).
- Promoters have pledged 1.4% of their shares.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q3 FY25)
SUNPHARMA Q3 FY25 results (consolidated figures, as filed on NSE).
Revenue was ₹13,675.46 crore, up 2.9% QoQ.
Net profit was ₹2,903.38 crore, down 4.5% QoQ.
Operating margin was 29.3%.
EPS was ₹12.1, down 4.7% QoQ.
SUNPHARMA के Q3 FY25 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹13,675.46 करोड़; पिछली तिमाही की तुलना में 2.9% की बढ़त।
शुद्ध मुनाफ़ा: ₹2,903.38 करोड़; पिछली तिमाही की तुलना में 4.5% की गिरावट।
ऑपरेटिंग मार्जिन: 29.3%।
EPS: ₹12.1; पिछली तिमाही की तुलना में 4.7% की गिरावट।
SUNPHARMAના Q3 FY25 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹13,675.46 કરોડ; ગયા ક્વાર્ટરની સરખામણીએ 2.9% વધારો.
ચોખ્ખો નફો: ₹2,903.38 કરોડ; ગયા ક્વાર્ટરની સરખામણીએ 4.5% ઘટાડો.
ઓપરેટિંગ માર્જિન: 29.3%.
EPS: ₹12.1; ગયા ક્વાર્ટરની સરખામણીએ 4.7% ઘટાડો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
28/100 · Neutral over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 0/30: Delivery 57.9% over the last 20 sessions vs 64.7% in the 40 before (0.89x); shares delivered per day 0.9x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 15/15: 89 schemes hold it, about ₹20,939 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 8/15: Verdict "Building", sustained score 44/100.
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Dividend ● Results
- 7 Jul 26Dividend Dividend ₹5 (ex-date) -1.3% next session
- 5 Feb 26Dividend Dividend ₹11 (ex-date) -0.5% next session
- 7 Jul 25Dividend Dividend ₹5.5 (ex-date) -0.2% next session
- 6 Feb 25Dividend Dividend ₹10.5 (ex-date) -0.2% next session
- 31 Jan 25Results Q3 FY25 results: net profit ₹2,903.4 cr +0.2% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Dec 2024 | ₹13,675 cr | ₹2,903 cr | — | 29.3% | 12.1 |
| Sept 2024 | ₹13,291 cr | ₹3,040 cr | +28.0% | 29.6% | 12.7 |
| Jun 2024 | ₹12,653 cr | ₹2,836 cr | +40.2% | 28.5% | 11.8 |
| Mar 2024 | ₹11,983 cr | ₹2,655 cr | +33.8% | 25.3% | 11.1 |
Shareholding trend
| Holder | Mar 2026 | Sept 2025 | Dec 2024 |
|---|---|---|---|
| Promoters | 54.48% | 54.48% | 54.48% |
| Foreign institutions (FII) | 15.93% | 16.55% | 18.05% |
| Domestic institutions (DII) | 21.11% | 20.23% | 18.55% |
| Mutual funds | 11.96% | 12.41% | 12.24% |
| Retail investors | 4.31% | 4.50% | 4.61% |
| Number of shareholders | 6,90,957 | 7,43,877 | 6,89,623 |
Common questions
What was Sun Pharmaceutical Industries Limited's latest quarterly profit?
Sun Pharmaceutical Industries Limited reported a net profit of ₹2,903 cr for the quarter ended Dec 2024, on revenue of ₹13,675 cr.
How much do promoters hold in Sun Pharmaceutical Industries Limited?
Promoters held 54.48% of Sun Pharmaceutical Industries Limited at the end of Mar 2026, with 1.42% of promoter shares pledged.
Is Sun Pharmaceutical Industries Limited debt-free?
Its latest reported debt-to-equity ratio is 0.06, which is very low.
What is Sun Pharmaceutical Industries Limited's P/E ratio?
About 38.9, based on the last 12 months' earnings and a price of ₹1,777.7 (data 2026-10-31).
What is the 52-week high and low of Sun Pharmaceutical Industries Limited?
The 52-week high is ₹2,046.9 and the 52-week low is ₹1,583.7.
Mutual funds holding Sun Pharmaceutical Industries Limited
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 89 schemes holding about ₹20,939 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| SBI Nifty 50 ETF | SBI Mutual Fund | 1.84% | ₹3,736 cr |
| SBI BSE Sensex ETF | SBI Mutual Fund | 2.28% | ₹2,635 cr |
| SBI Aggressive Hybrid Fund | SBI Mutual Fund | 1.67% | ₹1,439 cr |
| NIPPON INDIA ETF NIFTY 50 BEES | Nippon India Mutual Fund | 1.84% | ₹1,199 cr |
| NIPPON INDIA LARGE CAP FUND | Nippon India Mutual Fund | 2.18% | ₹1,118 cr |
| NIPPON INDIA PHARMA FUND | Nippon India Mutual Fund | 11.71% | ₹1,073 cr |
| SBI Large Cap Fund | SBI Mutual Fund | 1.90% | ₹995 cr |
| SBI Balanced Advantage Fund | SBI Mutual Fund | 1.67% | ₹677 cr |
| SBI Healthcare Opportunities Fund | SBI Mutual Fund | 11.14% | ₹654 cr |
| Nippon India ETF BSE Sensex | Nippon India Mutual Fund | 2.28% | ₹633 cr |
| Mirae Asset ELSS Tax Saver Fund | Mirae Asset Mutual Fund | 2.34% | ₹576 cr |
| Mirae Asset Large & Midcap Fund | Mirae Asset Mutual Fund | 1.26% | ₹540 cr |
| Mirae Asset Large Cap Fund | Mirae Asset Mutual Fund | 1.42% | ₹505 cr |
| SBI ELSS Tax Saver Fund | SBI Mutual Fund | 1.65% | ₹495 cr |
| Nippon India Multi Cap Fund | Nippon India Mutual Fund | 0.91% | ₹489 cr |
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹1,777.7 | ₹4,26,652 cr | 38.9 | 4.8 | 14.7% | 17.7% | 0.06 | +3.6% |
| Divi's Laboratories Limited | ₹9,780 | ₹2,57,903 cr | 88.8 | — | 16.2% | 18% | 0 | +49.4% |
| Torrent Pharmaceuticals Ltd | ₹4,613.4 | ₹1,76,300 cr | 75.6 | 9.6 | 27.1% | 13.5% | 1.79 | +28.0% |
| Laurus Labs Ltd. | ₹2,405.5 | ₹1,29,243 cr | 97.1 | 21.5 | 18.2% | 20.5% | 0.48 | +149.8% |
| Zydus Lifesciences Limited | ₹1,245.5 | ₹1,24,089 cr | 27.8 | — | 19.7% | 17.8% | 0.46 | +24.1% |
| Dr. Reddy's Laboratories Ltd. | ₹1,352 | ₹1,12,643 cr | 40.3 | 2.9 | 12.1% | 12.1% | 0.21 | +13.0% |
Compare SUNPHARMA with DIVISLAB in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open SUNPHARMA in NSE Scanner →